3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
2
Active not recruiting
2
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
1
Conditions
Multiple Myeloma
9
Burkitt Lymphoma
6
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Leukemia, Biphenotypic, Acute
3
Smoldering Multiple Myeloma
2
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
2
Lymphoma, Large B-Cell, Diffuse
2
Lung Neoplasms
2
Recurrence
1
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
1
Neoplasms
1
Neoplasm Metastasis
1
Myelodysplastic Syndromes
1
Meningioma
1
Lymphoma, B-Cell, Marginal Zone
1
Lymphoma
1
Leukemia, Myelomonocytic, Chronic
1
Immunoglobulin Light-chain Amyloidosis
1
Hodgkin Disease
1
Esophageal Neoplasms
1
Down Syndrome
1
Carcinoma, Non-Small-Cell Lung
1
Brain Neoplasms
1
Blastic Plasmacytoid Dendritic Cell Neoplasm
1
Interventions
Blood Specimen Collection
38
pembrolizumab
36
Bevacizumab
22
Surveys and Questionnaires
18
Standard of Care
18
Radiotherapy
18
Exercise
17
Carboplatin
16
Nivolumab
15
atezolizumab
14
Cisplatin
14
Drug Therapy
13
Paclitaxel
12
Fluorouracil
12
Cyclophosphamide
12
Cetuximab
12
Trastuzumab
10
Leucovorin
10
Docetaxel
10
Dexamethasone
10
Pemetrexed
9
Oxaliplatin
9
Biopsy
9
pertuzumab
8
olaparib
8
Temozolomide
8
Panitumumab
8
Observation
8
Irinotecan
8
abemaciclib
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Neoplasms
×
dexamethasone acetate
×
Clear all
NCT06979596
2026-05-13
OMAHA-015
Merck Sharp & Dohme LLC
Phase 2
Recruiting
250 enrolled